DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
June 18, 2009
205 JEFFERSON STREET
JEFFERSON CITY, MO 65101

Committee Members Present
Henry Petry, D.O., Chairman
Conrad Balcer, D.O.
Pat Bryant , PharmD
Gene Forrester, RPh

Committee Members Absent:
Joe Parks, MD
Steve Calloway, RPh

Contractors in Attendance:
Rick Pope, PharmD, First Health Services
Jennifer Kemp-Cornelius, PharmD, ACS-Heritage
Bethany Noble, ACS-Heritage
Tom Beetem, RPh, Infocrossing
Morgan Sperry, PharmD. UMKC-DIC
Jonathan Wear, UMKC-DIC

MO HealthNet Staff Present:
George L. Oestreich, PharmD, Dep. Division Director
Jay Bryant Wimp, RPh, Clinical Pharmacist
Allison Lauf, RN
Mary Heet, RN
Jayne Zemmer, Social Services Manager
Andrew Haslag, Fiscal Manager
Tisha McGowan, Unit Supervisor
Beth McQuaide, Special Assistant
DJ Johnson, Program Development Specialist
Lisa Clements, PhD, Clinical Director Psychology Program
Jenna Twehaus, RN
Renee Riley, Medicaid Specialist
Corey Lupardus, Correspondence and Information Spec.
Chad Maness, UMKC, Student Intern

Others Attending:

M. Patty Laster, Genentech	Rob Truckenmiller, UCB	David Chapman, UCB	Joe Summers, Takeda
John Stoner, Astra Zeneca	Molly Skelsey, Astra Zeneca	Mattew Stafford, Merck	Carol A. Curtis, Astra Zeneca
Angee McDaniel, Pfizer	Susan Zalenski, Johnson and Johnson		Jeff Knappen, Allergan
P. Wingbermuehle, Astra Zeneca	Todd Houldsworth, OMH	Gameal Collins, Novartis	Jim Maus, Student
John Solhtz, Eisai	Jeff Himmelberg, GSK	Peggy Brand, Roche	Phil King, Pfizer
Melissa Denno Pfizer	Brian Bocher, Pfizer	Eli Korner, Roche	Eric Blake, Schering Plough
Shelia Clayton, Schering Plough	Don Larsen, Forest	Grant Cale, BMS	Steve Wright, TPNA

Many names on the sign-in sheet were illegible. Sign in sheet on file for review.

Welcome, Introductions and Opening Remarks	Chairman, Henry Petry, D.O. called the meeting to order at 10:00 a.m. noting that Rhonda Driver, RPh, Director Pharmacy Program would not be in attendance and George L. Oestreich, PharmD, Deputy Division Director would be joining the meeting later. Chad Maness, Student Intern from UMKC was introduced.

Minutes Approval	Minutes of the meeting held March 12, 2009 were reviewed and approved as submitted.
Pharmacy Program/Budget Update	A PowerPoint presentation entitled "Aligning Forces for Change" was given by George L. Oestreich, PharmD, MPA, Deputy Division Director. Dr. Oestreich discussed current tools in place for clinical use. These include: SmartPA, Decision Support Tools (CyberFormance, Paid Claims Tool), CyberAccess and Care Connection. Tools in place for patient/participant use include Direct Inform which, is in beta test, and MoRx Price Compare. Current features of each tool were summarized as well as near and later term additions planned. Dr. Oestreich demonstrated how the current Health Information Technology (HIT) fits together in the MO HealthNet Program. He discussed how the tools are used to work with our state partners as well as the MHD role with private sector partners describing a statewide health information exchange model. Pharmacy Program performance was discussed including the impact of eligibility and off trend savings for all interventions. Dr. Oestreich also demonstrated a new page under development for the MHD Web page. This page will provide information on the Advisory Groups to the Clinical Services Unit, including the Drug Prior Authorization Committee. This slide presentation will be available on the site; which will be live in the very near future and found at http://dss.mo.gov/mhd/cs/advisory/index.htm. The remainder of the presentation was opened for questions from the Committee and the audience.
DUR Report	Tisha McGowan, DUR Coordinator reported the DUR Board reviewed, at their April meeting, and concurred with the recommendations made by the Drug Prior Authorization (PA) Committee at their March meeting, however a quorum was not established and the Board met as a Committee of the Whole. A conference call was convened in early May to ratify the recommendations made by the Committee of the Whole which included changes to the Statin PDL recommendation to allow for editing for secondary prevention parameters.
Old Business	
Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule had been updated with all edits approved at the last quarter's meetings. This schedule may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf
New Business	
New Drug Review	**Discussion –** A listing of products recommended for open access, clinical edit, as a preferred drug list (PDL) product or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending. Jay Bryant Wimp, RPh, Clinical Pharmacist reviewed MHD recommendations. Discussion surrounding Bupropion HBR (Aplenzin) ensued prompting the Committee to request an evidence based analysis from the Drug Information Center (DIC). Mr. Bryant Wimp noted current legislation prohibits limits on drugs of this nature. • **Public Hearing –** Angee McDaniel, PharmD addressed the group on behalf of Pfizer Pharmaceuticals and in support of the drug Toviaz. Dr. McDaniel presented clinical highlights of the product. She provided dosing, efficacy and safety data while discussing the metabolic pathway and 2 twelve week randomized, double blind, placebo controlled, phase three trials associated with the product. Dr. McDaniel also discussed 3 year safety data published on the product as well as a behavior modification program call "Your

	Way" which is given to the patient with sample product. This product is still under solicitation for the PDL, Dr Oestreich clarified questions from the audience and members on when the actual recommendation will be presented to the Committee. • **Decision –** Members voted to accept the new drug recommendations as presented, (See Roll Call Vote)
Clinical Edits **Selzetry®**	• **Discussion** – A copy of the proposed clinical edit criteria was provided in the meeting packet and as a handout to all attending. Mr. Bryant-Wimp reviewed the document noting this edit will also be tied to the Trofile proposal which is the next document in the meeting packet. Questions from the Committee were answered. • Public Hearing – No comments were entered. • Decision –The Committee voted to accept this edit as presented contingent upon having a positive Trofile test. (See Roll Call Votes)
Trofile™	• **Discussion** – A copy of the proposed clinical edit criterial was provided in the meeting packet and as a handout to all attending. Mr. Bryant-Wimp reviewed the document. Questions from the Committee were answered and discussion ensued surrounding where patients requiring this testing are being treated. It was clarified that at this point MHD does not have the ability to edit to provider sub specialty however the question can be added at the call center level or patient specific editing could be considered. • **Public Hearing** – No comments were entered. • **Decision** – A motion was made and seconded to require that this testing be ordered by appropriately trained physicians. The Committee voted to accept this edit with this addition. (See Roll Call Votes)
Suboxone®	• **Discussion** – A copy of the proposed updates to clinical edit criteria was provided in the meeting packet and as a handout to all attending. Mr. Bryant-Wimp reviewed the document. He noted the addition of additional counseling programs, in addition to CSTAR to approval criteria as well as a pregnancy indication to denial criteria. • Public Hearing – No comments were entered. • Decision – A motion was made and seconded to accept the proposal as submitted. The motion carried.(See Roll Call Votes)
Xolair®	• **Discussion** – A copy of the proposed updates to clinical edit criteria was provided in the meeting packet and as a handout to all attending. Mr. Bryant-Wimp reviewed the document. He noted these updates were determined as necessary after reviewing information noted at the call center level. Changes included the addition of RAST or in vitro reactivity in addition to skin testing and clarification of Trial and Failure definition to the approval criteria. • Public Hearing – No comments were entered. • Decision – A motion was made and seconded to accept the proposal as submitted. The motion carried.(See Roll Call Votes)
Preferred Drug List (PDL) Annual Review:	Products under review this quarter are currently on the PDL with contracts expiring in September. Recommended changes to the current edits were bolded on the criteria documents presented (See Meeting Packet), for easy identification. • **Discussion –**Mr. Bryant-Wimp reviewed the criteria document pointing out the addition of one product,

Beta Adrenergic Blockers and Diuretic Combinations	Nadolol/Bendroflumethiazide, to non preferred status. • **Public Hearing-** On behalf of Forest Pharmaceuticals and in support of the product Bystolic, Chris McCarthy, MD provided a history of Beta Blockers and discussed the different categories of Beta Blockers. Dr. McCarthy requested the Committee consider the differences offered by Bystolic especially in the African American and obese populations and consider the product for preferred status. Members requested utilization numbers on the product and discussion ensued surrounding the heterogeneous nature of the class. The recommendation to lower the number of preferred agents to 1 from 2 to get to a non-preferred agent was made. • **Decision –** Members voted to accept the edit with the change in the number of preferred agents required to try and fail from 2 to 1 before reaching a non-preferred agent. MHD will look at utilization six months post implementation. (See Roll Call Vote)
Calcium Channel Blocker/Dihydropyridines	• **Discussion –**Mr. Bryant-Wimp reviewed the criteria document. He noted the addition of one product, Nisoldipine, to the non preferred status. • **Public Hearing-** No comments were entered. • **Decision –** The Committee approved the edit as presented. (See Roll Call Vote)
Calcium Channel Blocker/Non Dihydropyridines	• **Discussion –** The group reviewed the proposed criteria document noting no change to the current coverage. • **Public Hearing-** No comments were entered. • **Decision –** The Committee approved the recommendation as presented. (See Roll Call Vote)
Angiotensin II Receptor Calcium Channel Blocker Combinations	• **Discussion –** The group reviewed the proposed criteria document noting no change to current coverage. • **Public Hearing-** No comments were entered. • **Decision –** A motion, second and vote to accept the edit were made. (See Roll Call Vote)
Cox II Inhibitors	• **Discussion –** Mr. Bryant-Wimp reviewed the criteria document pointing out there were no changes being recommended to the current PDL edit. Clinical criteria will remain in place. • **Public Hearing-**No comments were entered. • **Decision –** The Committee approved the edit as presented. (See Roll Call Vote)
Hepatitis C Agents	• **Discussion –** The group reviewed the criteria document pointing out there were no changes recommended to the current PDL criteria. All products in this class remain preferred. • **Public Hearing-** No comments were entered. • **Decision –** The group approved the recommendation as submitted. (See Roll Call Vote)
Amylin Analogs	• **Discussion –** The group reviewed the criteria document noting no change. All products in this category were recommended as preferred. Up front clinical criteria will remain in place. • **Public Hearing-**No comments were entered. • **Decision –** The Committee approved the edit as submitted. (See Roll Call Vote)
GLP-1 Receptor Agonists	• **Discussion –** Mr. Bryant-Wimp pointed out no change to this edit. Up front clinical criteria remain in place. • **Public Hearing-**No comments were entered.

	• **Decision –** Members approved the edit recommendation. (See Roll Call Vote)
DPP-IV Inhibitors	• **Discussion –**No change to the edit was recommended which includes the continuation of clinical criteria. • **Public Hearing-**No comments were entered. • **Decision –**The edit was approved as presented. (See Roll Call Vote)
Onychomycosis Antifungals	• **Discussion –** Mr. Bryant-Wimp reviewed the criteria document. No changes were recommended to the current PDL criteria. Members were reminded that diagnosis, dosing and duration of therapy parameters will remain in place. • **Public Hearing-**No comments were entered. • **Decision –** Motion, second and vote to approve the edit were made. (See Roll Call Vote)
Proton Pump Inhibitors	• **Discussion –** The group reviewed the criteria document noting changes to the non preferred products listed. The step therapy and approval diagnosis requirements within this edit remain unchanged as well. Discussion ensured surrounding the use of PPI's in hospitals and the continuation of use after discharge. • **Public Hearing-** Joe Summers spoke to the concerns of overuse of PPI's. Dr. Summers spoke in support of the new product Kapidex Capsules. He stated his practice viewed the product as an effective product. • **Decision –** The edit was approved as presented. (See Roll Call Vote)
Ribavirins	• **Discussion –**No change to the existing edit was recommended. • **Public Hearing-** No comments were entered. • **Decision –** The Committee approved the recommendation. (See Roll Call Vote)
Topical Immunomodulators	• **Discussion –** No changes were recommended to the current PDL criteria. All products in the class remain preferred. • **Public Hearing-**No comment was entered. • **Decision –** The edit was approved as submitted. (See Roll Call Vote)
Topical Androgenic Agents	• **Discussion –** No changes were recommended to the current PDL criteria. • **Public Hearing-**No comments were entered. • **Decision –** The edit was approved as submitted. (See Roll Call Vote)
Preferred Drug List Discussion/Therapeutic Classes	A handout of therapeutic categories to be considered for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This meeting will be an annual review of products with contracts expiring December 31, 2009. This handout was also provided to all attendees and will be posted to the Division's web page http//:www.dss.mo.gov.mhd.
Tramadol DUR Intervention	Jennifer Kemp-Cornelius, PharmD. ACS Healthcare Systems summarized the current clinical edit for Tramdol®/Ultram ER. Slides shared provided claim counts, paid amounts per participant and utilization data. Helpdesk approval/denial statistics were also shared. Dr. Kemp-Cornelius explained at each Drug Utilization Review Board meeting she would like to pick an edit that is not routinely reviewed each year as she reviewed each of the documents. This information can be shared with the PA Committee if there is an interest. The next topic will be Skeletal Muscle Relaxants.
Program Utilization Information	Dr. Oestreich reminded the group of the upcoming carve out of pharmacy services from Managed Care. A series of MO HealthNet News e-mail notices are planned to notify providers of the changes. MCO prior

	authorizations and grandfathering will apply. Members felt it was important to remind the pharmacy provider that they have the ability to call the help desk with information. Dr. Oestreich noted recent projects which included the implementation of the Optical program into SmartPA and patient level editing. The home and community based services partnership with Department of Health and Senior Services should be live in September. Dr. Oestreich asked members to let MHD know of information they would be interested in seeing at future meetings.
Top 25 Drugs by Cost	Top 25 drug list for dates of service between January 1, 2008 through February, 2009 was provided for the Committees' information. This report was provided in two formats; ranked by number of claims and ranked by amount paid. Copies were available to all attendees.
Clinical Edit Summary Report	An overview report of the clinical edit and prior authorization request transaction counts for the month of May 2009 was provide for all attending. The report provided total transaction counts as well has information on the outcome (approval or denial) of the request.
Call Center Statistics	A handout detailing pharmacy help desk call center activity was provided for all attending. Statistics for May 2009 were included.
Adjourn	Carol Curtis, Astra Zeneca requested a Committee Roster be sent to Lon Lowry, President PhRMA to be shared with the membership. Ms. Curtis asked for clarification on the additional clinical edit criteria under development for the statins and when this criteria might be implemented. The next meeting is scheduled for September 17, 2009. The Drug PA committee went into Executive Session for the sole purpose of discussing individual recipient specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See attached roll call) .

Roll Call Votes – June 18, 2009

Member	***New Drug Review Open Access***	***New Drug Review PDL Products***	***New Drug Review Clinical Edits***	***New Drug Review PA Cont.***	***Maraviroc***	***Trofile***	***Suboxone***	***Xolair***	***Beta Blocker***
Henry Petry, D.O.	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah
Gene Forrester, R. Ph.	***Motion***	**Second**	***Motion***	**Second**	**Second**	*Yeah*	Yeah	**Yeah**	Yeah
Steven Calloway, R. Ph.	Absent	*Absent*	Absent	*Absent*	Absent	*Absent*	Absent	*Absent*	*Absent*
Pat Bryant Pharm.D.	Yeah	Yeah	***Second***	Yeah	Yeah	**Second**	**Second**	**Second**	**Secon**d
Conrad Balcer, D.O.	**Second**	***Motion***	*Yeah*	***Motion***	**Motion**	**Motion**	**Motion**	***Motion***	***Motion***
Joe Parks, M.D.	Absent	*Absent*	Absent	*Absent*	Absent	*Absent*	Absent	*Absent*	*Absent*

Member	***CCB/ Dihydropyridines***	***CCB Non Dihydropyridines***	***CCB/ ARB***	***CoxII***	***Hep C***	***Amylin Analogs***	***GLP-1***
Henry Petry, D.O.	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah
Gene Forrester, R. Ph.	**Second**	**Second**	Yeah	Yeah	**Second**	Yeah	**Second**
Steven Calloway, R. Ph.	Absent	*Absent*	Absent	*Absent*	Absent	*Absent*	Absent
Pat Bryant, Pharm.D.	Yeah	Yeah	***Motion***	**Second**	*Yeah*	***Motion***	***Motion***
Conrad Balcer, D.O.	***Motion***	***Motion***	**Second**	***Motion***	***Motion***	**Second**	*Yeah*
Joe Parks, M.D.	Absent	*Absent*	Absent	*Absent*	Absent	*Absent*	Absent

Member	***DPP-I***	***Onychomycosis***	***PPI***	***Ribavirins***	***Top Immun***	***Top Androgenic***	***Closed Session***	***Adjourn***
Henry Petry, D.O.	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah	Yeah
Gene Forrester, R. Ph.	*Yeah*	**Second**	**Second**	**Second**	Yeah	**Motion**	**Second**	**Second**
Steven Calloway, R. Ph.	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent
Pat Bryant, Pharm.D.	**Motion**	Yeah	Yeah	Yeah	**Second**	**Second**	**Second**	**Second**
Conrad Balcer, D.O.	**Second**	**Motion**	***Motion***	**Motion**	***Motion***	Yeah	***Motion***	***Motion***
Joe Parks, M.D.	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent

EXECUTIVE SESSION
June 18, 2009

ommittee Members Present
Henry Petry, D.O., Chairman
Conrad Balcer, D.O.
Pat Bryant , PharmD
Gene Forrester, RPh

Committee Members Absent:
Joe Parks, MD
Steve Calloway, RPh

Contractors in Attendance:
Rick Pope, PharmD, First Health Services
Jennifer Kemp-Cornelius, PharmD, ACS-Heritage
Bethany Noble, ACS-Heritage
Tom Beetem, RPh, Infocrossing
Morgan Sperry, PharmD. UMKC-DIC
Jonathan Wear, UMKC-DIC

MO HealthNet Staff Present:
George L. Oestreich, PharmD, Dep. Division Director
Jay Bryant Wimp, RPh, Clinical Pharmacist PasPPPat
Allison Lauf, RN
Mary Heet, RN
Jayne Zemmer, Social Services Manager
Andrew Haslag, Fiscal Manager
Tisha McGowan, Unit Supervisor
Beth McQuaide, Special Assistant
DJ Johnson, Program Development Specialist
Lisa Clements, PhD, Clinical Director Psychology Program
Jenna Twehaus, RN
Renee Riley, Medicaid Specialist
Corey Lupardus, Correspondence and Information Spec.
Chad Maness, UMKC, Student Intern

	EXECUTIVE SESSION
Minutes Review	Minutes of the March 2009 Executive Session were approved as submitted
Case Reviews	No cases were presented for review.
Adjourn	Executive session adjourned. (See role call vote)